1Smit W, Schouten N, van den Berg N, et al. Analysis of he prevalence and causes of ultrafiltration failure during long - term peritoneal dialysis : a cross - sectional study [ J ]. Perit Dial Int,2004,24 : 506 - 508.
2Ho-dac-Pannekeet MM, Atasever B, Struijk DG, et al. Analysis of uhrafiltration failure in peritoneal dialysis patients by means of standard peritoneal permeability analysis[ J]. Perit Dial Int,1997, 17: 144 - 150.
3Rippe B, Venturoli D. Simulations of osmotic ultrafiltration failure in CAPD using a serial three - pore membrane/fiber matrix model [ J]. Am J Physiol Renal Physio1,2007,292 : F1 035 - 43.
4Ni J, Verbavatz JM, Rippe A, et al. Aquaporin- 1 plays an essential role in water permeability and ultrafiltration during peritoneal dialysis[ J]. Kidney Int, 2006,69 : 1 518 - 25.
5Williams JD, Craig KJ, Topley N, et al. Peritoneal Biopsy Study Group : Morphologic changes in the peritoneal membrane of patients with renal disease[ J]. J Am Soc Nephrol,2002 ,13 :470 -479.
6De Vriese AS,Tihon FG, Stephan CG. et al. Diabetes induced mi crovascular proliferation and hypermeability in the peritoneum Role of vascular endothelial growth factor[ J]. J Am Soc Nephrol 2001,12:1 734 - 1 741.
7Toi M, Matsumoto T, Bnado H. Vascular endothelial growth factor: its prognostic, predictive and therapeutic implications [ J]. Lancet Oncol,2001,2 :667 - 673.
8Neufeld G, ChoenT, Gengrinoritch S, et al. Vascular endothelial growth factor and its receptors[ J]. FASEB J, 1999,13:9 -22.
9Duyndma MC, Hilhorst MC, Schluper HM, et al. Vascular endothelial growth factor-165 over expression stimulates angiogenesis and induces cyst formation and macrophage infiltration in human ovarian cancer xenografts[ J ]. Am J Pathol,2002,160:537 - 54.
10Olofsson B, Jehsh M, Eriksso U, et al. Current biology of VEGF-B and VEGF-C [ J]. Curr Opin Biotechnol, 1999,10:528 -535.
二级参考文献8
1De Vriese AS, Tilton RG, Stephan CG, et al. Diabetes induced microvascular proliferation and hypermeability in the peritoneum:Role of vascular endothelial growth factor. J Am Soc Nephrol, 2001,12:1734-1741
2Neufeld G, Choen T, Gengrinoritch S, et al. Vascular endothelial growth factor and its receptors. FASFB J, 1999, 13:9-22
3Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature, 2001, 414:813-820
4De Vriese AS, Moritier S, Lameire NH. Glucotoxicity of the peritoneal membrane:the case for VEGF. Nephrol Dial Transplant,2001,16:2299-2302
5Williams JD, Craig KJ, Topley N, et al. Peritoneal Biopsy Study Group:Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol, 2002, 13:170-179
6Margette PJ, Cyorffy S, Klob M, et al. Antiangiogenic and antifibrotic gene therapy in a chronic infusion model of peritoneal dialysis in rats. J Am Soc Nephrol, 2002, 13:721-728
7Combet S, Miyata T,Moulin P, et al. Vascular proliferation and enhanced expression of endothelial nitric oxide synthase in human peritoneum exposed to long-term peritoneal dialysis. J Am Soc Nephrol, 2000, 11:717-728
8Inagi R, Miyata T, Yamamot O, et al. Glucose degradation product methylglyoxal enhances the vascular endothelial growth factor in peritoneal cells;Role in the function and morphological alterations of peritoneal membranes in peritoneal dialysis.FEBS Lett, 1999, 463:260-264
